MEI Pharma, Inc. Share Price London S.E.
Equities
0JW9
US55279B3015
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.336 USD | -91.91% | +52.68% | -25.50% |
Sales 2024 * | 65.3M 5.15B | Sales 2025 * | 6.25M 493M | Capitalization | 19.06M 1.5B |
---|---|---|---|---|---|
Net income 2024 * | 26M 2.05B | Net income 2025 * | -40M -3.15B | EV / Sales 2024 * | 0.29 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.05 x |
P/E ratio 2024 * |
0.79
x | P/E ratio 2025 * |
-0.5
x | Employees | 46 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.3% |
Latest transcript on MEI Pharma, Inc.
1 day | -91.91% | ||
1 week | +52.68% | ||
Current month | +49.78% | ||
1 month | +38.09% | ||
3 months | +9.76% | ||
6 months | -32.20% | ||
Current year | -25.50% |
Managers | Title | Age | Since |
---|---|---|---|
David Urso
CEO | Chief Executive Officer | 60 | 06/03/14 |
Justin File
DFI | Director of Finance/CFO | 53 | 11/06/23 |
Caroline Ruiz
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 73 | 25/02/18 |
Thomas Reynolds
BRD | Director/Board Member | 65 | 10/02/13 |
Charles Baltic
CHM | Chairman | 63 | 19/10/11 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.36% | 52.5B | |
+36.73% | 39.31B | |
-8.63% | 39.01B | |
+25.46% | 28.2B | |
-11.17% | 26.57B | |
+11.44% | 26.2B | |
+45.09% | 14.15B | |
+32.93% | 12.62B | |
-5.30% | 11.74B |
- Stock Market
- Equities
- MEIP Stock
- 0JW9 Stock